Cancer Cell：乔源远团队发现神经内分泌前列腺癌的代谢弱点，提出联合治疗新策略
Ranking
No observed public metrics; popularity remains neutral/archived.
Merged summary
TL;DR — A Cancer Cell paper (Aug 3, 2026) from Yuanyuan Qiao and Arul Chinnaiyan at the University of Michigan (Ann Arbor) identifies a "stress-adaptive lipid (kinase) axis" that neuroendocrine prostate cancer (NEPC) depends on to survive hypoxic, ER-stressed niches, and shows that co-inhibiting the lipid kinase PIKfyve and fatty acid synthase (FASN) is synthetically lethal. It matters because NEPC is a highly aggressive, treatment-resistant subtype with ~7-month median survival whose only real option is short-lived, toxic platinum chemotherapy.
- NEPC biology and the PIKfyve dependency: NEPC (loss of AR signaling, gain of SYP/NSE markers, frequent RB1/TP53/PTEN loss, FOXA2/SOX2/ASCL1/ONECUT2 lineage programs) grows under severe hypoxia with chronic ER stress and a persistently active PERK–ATF4 UPR branch. It overexpresses PIKfyve, which sustains endolysosomal trafficking, autophagic flux, and lipid recycling to maintain metabolic homeostasis.
- Selective vulnerability: PIKfyve knockout or inhibition disrupts lysosomal function, worsens ER stress, and kills NEPC cells while sparing conventional prostate cancer cells; tumors with high baseline ER stress are the most sensitive.
- Compensatory escape route: Surviving cells activate SREBP-dependent de novo fatty acid/lipid synthesis to offset lysosomal dysfunction — the second arm of the axis — which creates a synthetic-lethal relationship between PIKfyve and FASN.
- Combination efficacy: The PIKfyve inhibitor ESK981 plus the FASN inhibitor TVB-2640 acted synergistically across cell lines, patient-derived organoids, and PDX models, amplifying ER stress and converting the UPR from protective to terminal/pro-apoptotic, inducing apoptosis and extending survival, with some models reaching complete response.
- Translational outlook: Adding cisplatin further prolonged progression-free survival in animal models without notable added toxicity, and both drug classes are already in clinical trials, supporting near-term clinical testing.
Emphasis differs by source: 生物世界 focuses on the mechanistic/molecular chain (lineage programs, lysosomal-to-lipogenesis switch), while BioArt stresses clinical context (~7-month survival), the named drugs, and the multi-model/cisplatin translational evidence. Both are Chinese-language WeChat write-ups of the paper, not the primary article; this is biomedical/oncology research rather than an AI-methods advance.
Sources (2)
Cancer Cell：乔源远团队发现神经内分泌前列腺癌的代谢弱点，提出联合治疗新策略
TL;DR - A Cancer Cell paper (Aug 3, 2026) from Yuanyuan Qiao's team at University of Michigan Ann Arbor identifies a "stress-adaptive lipid kinase axis" that lets neuroendocrine prostate cancer (NEPC) survive hypoxic, ER-stressed niches, and shows that co-inhibiting PIKfyve and FASN kills tumor cells. It matters because NEPC currently relies on short-lived, toxic platinum chemotherapy, so a synthetic-lethal metabolic target offers a new treatment route.
- NEPC (AR-signaling loss, gain of SYP/NSE markers, frequent RB1/TP53/PTEN loss, FOXA2/SOX2/ASCL1/ONECUT2 lineage programs) overexpresses the lipid kinase PIKfyve, which sustains lysosomal degradation and lipid recycling to maintain metabolic homeostasis under hypoxia.
- PIKfyve inhibition disrupts lysosomal function and worsens ER stress; tumors with high baseline ER stress are more sensitive to it.
- Cells compensate via an SREBP-dependent de novo lipogenesis program, creating a synthetic vulnerability between PIKfyve and fatty acid synthase (FASN).
- Dual PIKfyve + FASN inhibition synergistically amplifies ER stress, triggers a terminal unfolded protein response, induces apoptosis, and extends survival in preclinical models.
Cancer Cell | 乔源远团队揭示神经内分泌前列腺癌代谢“致命弱点”，提出全新联合治疗策略
TL;DR - A Cancer Cell paper from Yuanyuan Qiao and Arul Chinnaiyan (University of Michigan) identifies a "stress-adaptive lipid axis" that neuroendocrine prostate cancer (NEPC) depends on for survival, and shows that co-inhibiting the lipid kinase PIKfyve and fatty acid synthase (FASN) is synthetically lethal. It matters because NEPC is a highly aggressive, treatment-resistant subtype with ~7-month median survival and only limited platinum chemotherapy options.
- NEPC grows under severe hypoxia with chronic ER stress; it sustains a persistently active PERK–ATF4 UPR branch and overexpresses PIKfyve, making it selectively dependent on PIKfyve-driven endolysosomal trafficking and autophagic flux — knockout or inhibition kills NEPC cells while sparing conventional prostate cancer cells.
- PIKfyve inhibition triggers a compensatory escape route: SREBP activation drives de novo fatty acid/lipid synthesis to offset lysosomal dysfunction, defining the second arm of the proposed stress–lipid adaptation axis.
- Combining the PIKfyve inhibitor ESK981 with the FASN inhibitor TVB-2640 acted synergistically across cell lines, patient-derived organoids, and PDX models, converting the UPR from protective to pro-apoptotic and extending survival, with some models reaching complete response.
- Adding cisplatin further prolonged progression-free survival in animal models without notable added toxicity; both drug classes are already in clinical trials, supporting near-term translational testing.
Note: this summary is based on a Chinese-language WeChat write-up (BioArt) of the paper, not the primary article; it is biomedical/oncology research rather than an AI-methods advance.